Patents Assigned to CureVac SE
  • Patent number: 12036277
    Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
    Type: Grant
    Filed: March 5, 2024
    Date of Patent: July 16, 2024
    Assignee: CureVac SE
    Inventors: Karl-Josef Kallen, Thomas Kramps, Margit Schnee, Benjamin Petsch, Lothar Stitz
  • Publication number: 20240229075
    Abstract: The present invention provides a nucleic acid sequence comprising at least one miRNA binding site sequence containing at least one miRNA binding site. Those miRNA binding site sequences are located within and/or immediately 3 or 5? of the 5? UTR of a gene to reduce the off-target side effects and allow a cell type specific expression from the nucleic acid sequence within the target organ or organs. The invention further provides pharmaceutical compositions, as well as a method of promoting cell-type specific expression, comprising the nucleic acid sequence according to the invention for use in therapy.
    Type: Application
    Filed: May 3, 2022
    Publication date: July 11, 2024
    Applicant: CureVac SE
    Inventors: Moritz THRAN, Sandra LAZZARO, Mallika RAMAKRISHNAN
  • Publication number: 20240197857
    Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
    Type: Application
    Filed: March 5, 2024
    Publication date: June 20, 2024
    Applicant: CureVac SE
    Inventors: Karl-Josef KALLEN, Thomas KRAMPS, Margit SCHNEE, Benjamin PETSCH, Lothar STITZ
  • Publication number: 20240181037
    Abstract: The present invention relates to carrier-formulated mRNA comprising at least one coding sequence encoding an influenza HA stem polypeptide, and to related aspects.
    Type: Application
    Filed: March 25, 2022
    Publication date: June 6, 2024
    Applicants: GLAXOSMITHKLINE BIOLOGICALS SA, CUREVAC SE
    Inventors: Hans Wolfgang GROßE, Edith JASNY, Janine MÜHE, Ventzislav Bojidarov VASSILEV, Clarisse LORIN, Nadia OUAKED, Corey MALLETT, Ronan ROUXEL, Normand BLAIS
  • Publication number: 20240156949
    Abstract: The present invention is directed to nucleic acids suitable for use in treatment or prophylaxis of an infection with a coronavirus, such as a Coronavirus SARS-CoV-2 variant, or a disorder related to such an infection, such as COVID-19. The present invention is also directed to compositions, and vaccines. The compositions and vaccines comprise at least one of said nucleic acid sequences, and nucleic acid sequences in association with a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acids, the composition, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, such as a Coronavirus infection from a SARS-CoV-2 variant.
    Type: Application
    Filed: October 26, 2023
    Publication date: May 16, 2024
    Applicants: GlaxoSmithKline Biologicals SA, CureVac SE
    Inventors: Benjamin PETSCH, Dominik VAHRENHORST, Diego CHAVES MORENO, Janina GERGEN, Jessica Michelle DEVANT, Kristina KOVACIKOVA, Hans Wolfgang GROßE
  • Publication number: 20240156946
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: December 21, 2021
    Publication date: May 16, 2024
    Applicants: CUREVAC SE, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nicole ROTH, Diego Chaves MORENO, Hans Wolfgang GROßE, Dominik VAHRENHORST, Susanne RAUCH
  • Publication number: 20240150386
    Abstract: The present invention is directed to a method for modifying the retention time of RNA on a chromatographic column. The present invention also concerns a method for purifying RNA from a mixture of at least two RNA species. Furthermore, the present invention relates to a method for co-purifying at least two RNA species from a mixture of at least two RNA species. In particular, the present invention provides a method for harmonizing the numbers of A and/or U nucleotides in at least two RNA species. The present invention is also directed to RNA obtainable by said methods, a composition comprising said RNA or a vaccine comprising said RNA and methods for producing such RNA and compositions. Further, the invention concerns a kit, particularly a kit of parts, comprising the RNA, composition or vaccine. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the RNA, composition and vaccine.
    Type: Application
    Filed: May 19, 2023
    Publication date: May 9, 2024
    Applicant: CureVac SE
    Inventors: Stefan HEINZ, Tilmann ROOS, Dominik VAHRENHORST, Markus CONZELMANN
  • Patent number: 11975064
    Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: May 7, 2024
    Assignee: CureVac SE
    Inventors: Karl-Josef Kallen, Thomas Kramps, Margit Schnee, Benjamin Petsch, Lothar Stitz
  • Publication number: 20240131142
    Abstract: The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition.
    Type: Application
    Filed: January 4, 2024
    Publication date: April 25, 2024
    Applicants: CureVac SE, Sanofi Pasteur
    Inventors: Patrick BAUMHOF, Wolfgang GROSSE, Edith JASNY, Thomas KRAMPS, Daniel VOSS, Julia DANNENMAIER, Valérie LECOUTURIER, Yves GIRERD-CHAMBAZ
  • Patent number: 11964012
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: March 6, 2023
    Date of Patent: April 23, 2024
    Assignee: CureVac SE
    Inventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
  • Patent number: 11965000
    Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.
    Type: Grant
    Filed: September 7, 2023
    Date of Patent: April 23, 2024
    Assignee: CureVac SE
    Inventors: Thomas Kramps, Margit Schnee, Daniel Voss, Benjamin Petsch
  • Patent number: 11964011
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: March 6, 2023
    Date of Patent: April 23, 2024
    Assignee: CureVac SE
    Inventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
  • Publication number: 20240100142
    Abstract: The invention relates to a method for producing a ribonucleic acid (RNA) molecule composition comprising n different RNA molecule species, the method comprising a step of RNA in vitro transcription of a mixture of m different deoxyribonucleic acid (DNA) molecule species in a single reaction vessel in parallel, i.e. simultaneously, and a step of obtaining the RNA molecule composition. Also provided is the RNA composition provided by the inventive method and a pharmaceutical composition comprising the same as well as a pharmaceutical container. Moreover, the invention provides the RNA composition and the pharmaceutical composition for use as medicament.
    Type: Application
    Filed: May 11, 2023
    Publication date: March 28, 2024
    Applicant: CureVac SE
    Inventors: Tilmann ROOS, Martin KUNZE, Benyamin YAZDAN PANAH, Salih YILMAZ, Markus CONZELMANN
  • Publication number: 20240102065
    Abstract: The present invention provides a method of reducing the immunostimulatory properties of an in vitro transcribed RNA by producing the in vitro transcribed RNA comprising a 3? terminal A nucleotide. Hereby, the circular DNA template used to generate the in vitro transcribed RNA has been linearized using a type IIS endonuclease. The invention further provides pharmaceutical compositions comprising the vitro transcribed RNA comprising a 3? terminal A nucleotide according to the invention for use in therapy.
    Type: Application
    Filed: January 26, 2022
    Publication date: March 28, 2024
    Applicant: CureVac SE
    Inventors: Moritz THRAN, Andreas THESS, Fabian EBER, Dipankar BHANDARI
  • Publication number: 20240101608
    Abstract: The present invention provides optimized nucleic acid molecules, methods for optimization of nucleic acid molecules and uses of optimized nucleic acid molecules. A modular design principle is provided that is suitable to generate a nucleic acid, particularly mRNA, which is tailored for a respective application. The nucleic acid molecules of the present invention can be obtained by the versatile combination of multiple modules on nucleic acid level. Such nucleic acid, e.g. mRNA, can be tailored by combining one or more modules, comprising (i) a nucleic acid moiety encoding a polypeptide of interest (e.g. a protein potentially producing a therapeutic outcome) and (ii) at least one further coding or non-coding nucleic acid moiety, e.g.
    Type: Application
    Filed: December 4, 2023
    Publication date: March 28, 2024
    Applicant: CureVac SE
    Inventors: Patrick BAUMHOF, Susanne RAUCH, Aleksandra KOWALCZYK, Johannes LUTZ, Edith JASNY, Benjamin PETSCH, Andreas THESS, Thomas SCHLAKE, Mariola FOTIN-MLECZEK, Regina HEIDENREICH, Sandra LAZZARO, Fatma FUNKNER, Wolfgang GROSSE
  • Publication number: 20240091344
    Abstract: The present invention relates to mRNAs suitable for use as mRNA-based vaccines against infections with MERS coronaviruses. Additionally, the present invention relates to a composition comprising the mRNAs and the use of the mRNAs or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of MERS coronavirus infections. The present invention further describes a method of treatment or prophylaxis of infections with MERS coronavirus using the mRNA sequences.
    Type: Application
    Filed: November 20, 2023
    Publication date: March 21, 2024
    Applicant: CureVac SE
    Inventor: Susanne RAUCH
  • Patent number: 11931406
    Abstract: The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: March 19, 2024
    Assignees: CureVac SE, Sanofi Pasteur
    Inventors: Patrick Baumhof, Wolfgang Grosse, Edith Jasny, Thomas Kramps, Daniel Voss, Julia Dannenmaier, Valérie Lecouturier, Yves Girerd-Chambaz
  • Publication number: 20240075116
    Abstract: The present invention relates to an RNA encoding a tumor antigen. In particular, the present invention relates to RNA suitable for treatment and/or prophylaxis of cancer and related diseases. The present invention concerns such RNA as well as compositions, vaccines and kits comprising the RNA. Furthermore, the present invention relates to the RNA, compositions, vaccines or kits as disclosed herein for use in the treatment and/or prophylaxis of cancer and related diseases.
    Type: Application
    Filed: March 13, 2023
    Publication date: March 7, 2024
    Applicant: CureVac SE
    Inventors: Mariola FOTIN-MLECZEK, Ingmar HOERR
  • Patent number: 11918643
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: March 5, 2024
    Assignees: CUREVAC SE, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nicole Roth, Diego Chaves Moreno, Hans Wolfgang Große, Dominik Vahrenhorst, Susanne Rauch
  • Patent number: 11920174
    Abstract: The present invention relates to analysis of an RNA molecule. It further relates to the use of this method for the quality control of an RNA molecule produced by in vitro transcription or for the quality control of an RNA molecule produced by chemical synthesis.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: March 5, 2024
    Assignee: CureVac SE
    Inventors: Fabian Johannes Eber, Aniela Wochner, Tilmann Roos